Healthcare

Valion Bio Reports Completion of 200-Liter Entolimod Production Run

Valion Bio reported that Velocity Bioworks completed a 200-liter non-GMP Entolimod production run in San Antonio, with the resulting drug substance meeting predefined acceptance criteria for the assessed quality attributes.

Published:
Reading Time
3 min

Valion Bio, Inc. (NASDAQ:VBIO) reported that its wholly owned subsidiary, Velocity Bioworks, completed a 200-liter non-GMP production run of Entolimod at its facility in San Antonio, Texas. The company said the run produced drug substance that met all predefined acceptance criteria for the quality attributes assessed.

#Production Results and Study Supply

The manufacturing work took place from May through June 2026. Valion Bio said productivity was approximately 27% higher than historical manufacturing data. Drug product from the run was filled in June and is supplying the company’s ongoing Entolimod study.

The study is fully funded by the National Institute of Allergy and Infectious Diseases’ Radiation and Nuclear Countermeasures Program under an Interagency Agreement with the Uniformed Services University and the Armed Forces Radiobiology Research Institute.

#Comparison With Earlier Manufacturing Run

The 200-liter production run followed a 50-liter run completed in January 2026. Dean Zikria, Valion Bio’s Interim Chief Executive Officer, said the latest run increased production scale fourfold while also improving productivity and yielding more drug substance per liter of fermentation volume.

The company said it expects to use the information from the run while planning future CGMP manufacturing for Entolimod. Valion Bio also continues to evaluate strategic alternatives for Velocity Bioworks.

#Entolimod Development Programme

Valion Bio is developing Entolimod as a potential medical countermeasure for Acute Radiation Syndrome under the U.S. Food and Drug Administration’s Animal Rule. The candidate has received Fast Track and Orphan Drug designations from the FDA.

Entolimod is described by the company as a Toll-like Receptor 5 agonist intended to activate NF-κB signalling pathways associated with cellular protection, tissue recovery and immune response. Valion Bio holds an exclusive, worldwide licence from Statera Biopharma to develop and commercialise Entolimod for Acute Radiation Syndrome, radiation-induced neutropenia and other indications.

#Valion Bio and Velocity Bioworks

Valion Bio is a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation in conditions involving radiation, disease and immune dysregulation.

Its pipeline also includes Entolasta, a next-generation TLR5 agonist being developed for potential broader applications including oncology supportive care, as well as potential programmes in neutropenia and immune dysfunction.

Velocity Bioworks is Valion Bio’s wholly owned biologics contract development and manufacturing organisation. The subsidiary has mammalian and microbial capabilities and focuses on manufacturing control, cost reduction, development timelines and domestic supply-chain security.

#Forward-Looking Statements

Valion Bio said statements concerning future CGMP manufacturing, Entolimod’s development and regulatory advancement, the potential applications of Entolasta, government or other entities’ interest in stockpiling countermeasures, additional capital and continued Nasdaq Capital Market listing are subject to risks and uncertainties. The company cautioned that actual results may differ from those described in its forward-looking statements and said it undertakes no duty to update them except as required by applicable law.

#Key Takeaways

  • Velocity Bioworks completed a 200-liter non-GMP Entolimod production run in San Antonio, Texas.
  • Valion Bio reported productivity approximately 27% higher than historical manufacturing data.
  • The resulting drug substance met all predefined acceptance criteria for the quality attributes assessed.
  • Drug product filled in June is supplying an ongoing study funded by NIAID/RNCP under an agreement involving USU and AFRRI.
  • Valion Bio expects to apply the manufacturing results to future CGMP planning and continues to evaluate strategic alternatives for Velocity Bioworks.

Original source: Read original article

Frequently Asked Questions